(Q36158684)

12 August 2017

1 reference

title

B cells as a therapeutic target in autoimmune diseases (English)

1 reference

12 August 2017

5

Cornelia M Weyand

1 reference

12 August 2017

Yong Wook Park

1

1 reference

12 August 2017

Sergey Pryshchep

series ordinal

2

1 reference

12 August 2017

Thorsten M Seyler

series ordinal

3

1 reference

12 August 2017

Jörg J Goronzy

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Therapeutic Targets

12 August 2017

published in

1 reference

12 August 2017

volume

9

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

431-445

1 reference

The role of autoantibodies in autoimmune disease

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The complement system as a therapeutic target in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Emerging approaches for the therapy of autoimmune and chronic inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

New roles for rheumatoid factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Costimulation blockade in the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The TNF and TNF receptor superfamilies: integrating mammalian biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF mediates survival of peripheral immature B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The uncertain glory of APRIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

APRIL-deficient mice have normal immune system development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

The current status of targeting BAFF/BLyS for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

TWE-PRIL; a fusion protein of TWEAK and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

BAFF production by antigen-presenting cells provides T cell co-stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

T-cell regulation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.431

21 January 2018

Identifiers

DOI

10.1517/14728222.9.3.431

1 reference

release_diam4f7qnfdd3dlsk6tnp4gxfu

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/diam4f7qnfdd3dlsk6tnp4gxfu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference